C 
ChongQing Zhengchuan Pharmaceutical Packaging Co 603976.SS · CNY
Health Care · Shanghai · 🇨🇳 China
30.65
+2.61%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in CNY, from our data supplier.
Revenue
CN¥664.4m
FY2016FY2025
Net income
CN¥18.9m
FY2016FY2025
Free cash flow
CN¥109.4m
FY2016FY2025
Shareholders' equity
CN¥1.21bn
FY2016FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥664.4m | CN¥801.1m | CN¥900.6m | CN¥796.2m | CN¥796.7m | CN¥502.0m | CN¥521.1m | CN¥595.8m | CN¥508.7m | CN¥470.0m |
| Research and development | CN¥14.5m | CN¥20.3m | CN¥23.4m | CN¥19.1m | CN¥12.1m | CN¥8.3m | CN¥5.3m | CN¥2.9m | CN¥31,114 | CN¥20.8m |
| Operating income | CN¥48.1m | CN¥65.3m | CN¥44.9m | CN¥58.8m | CN¥127.5m | CN¥61.9m | CN¥71.9m | CN¥94.1m | CN¥96.7m | CN¥79.3m |
| Net income | CN¥18.9m | CN¥53.2m | CN¥40.3m | CN¥64.8m | CN¥106.6m | CN¥53.1m | CN¥61.1m | CN¥82.8m | CN¥82.2m | CN¥70.5m |
| Diluted earnings per share | 0.14 | 0.35 | 0.27 | 0.44 | 0.70 | 0.36 | 0.39 | 0.56 | 1.24 | 0.62 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | CN¥1.90bn | CN¥1.96bn | CN¥2.04bn | CN¥2.01bn | CN¥1.96bn | CN¥1.32bn | CN¥1.24bn | CN¥1.13bn | CN¥1.06bn | CN¥621.1m |
| Cash and short-term investments | — | CN¥249.5m | CN¥437.7m | CN¥371.5m | CN¥646.9m | CN¥269.3m | CN¥368.2m | CN¥387.1m | CN¥433.2m | CN¥76.8m |
| Total liabilities | CN¥696.4m | CN¥733.4m | CN¥827.4m | CN¥823.5m | CN¥794.5m | CN¥284.2m | CN¥205.0m | CN¥139.4m | CN¥107.8m | CN¥106.0m |
| Debt | CN¥445.9m | CN¥432.0m | CN¥446.3m | CN¥460.2m | CN¥433.5m | CN¥49.7m | CN¥74.3m | CN¥13.0m | CN¥6.0m | CN¥10.0m |
| Shareholders' equity | CN¥1.21bn | CN¥1.22bn | CN¥1.22bn | CN¥1.18bn | CN¥1.17bn | CN¥1.04bn | CN¥1.04bn | CN¥987.0m | CN¥953.9m | CN¥515.1m |
| Shares outstanding | 133m | 150m | 150m | 149m | 152m | 148m | 155m | 149m | 66m | 114m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | CN¥136.5m | CN¥112.2m | CN¥194.2m | CN¥38.4m | CN¥105.0m | CN¥121.8m | CN¥55.3m | CN¥64.3m | CN¥52.5m | CN¥25.7m |
| Capital spending | −CN¥27.1m | −CN¥72.0m | −CN¥90.0m | −CN¥276.1m | −CN¥137.5m | −CN¥175.9m | −CN¥111.7m | −CN¥69.2m | −CN¥40.5m | −CN¥8.9m |
| Free cash flow | CN¥109.4m | CN¥40.2m | CN¥104.2m | −CN¥237.7m | −CN¥32.6m | −CN¥54.1m | −CN¥56.4m | −CN¥4.9m | CN¥12.0m | CN¥16.8m |
| Dividends paid | −CN¥44.5m | −CN¥50.7m | −CN¥13.3m | −CN¥49.6m | −CN¥6.2m | −CN¥48.6m | −CN¥12.1m | −CN¥49.7m | −CN¥4.1m | −CN¥18.1m |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥172.0m | CN¥208.6m | CN¥206.6m | CN¥134.1m | CN¥162.1m | CN¥161.6m | CN¥191.5m | CN¥148.9m |
| Operating income | CN¥12.0m | CN¥20.0m | CN¥12.9m | CN¥1.5m | CN¥3.4m | CN¥12.1m | CN¥4.5m | CN¥9.3m |
| Net income | CN¥5.5m | CN¥6.8m | CN¥2.6m | CN¥2.3m | CN¥3.2m | CN¥10.9m | CN¥1.3m | CN¥7.6m |
| Diluted earnings per share | 0.04 | 0.05 | 0.02 | 0.02 | 0.02 | 0.08 | 0.01 | 0.05 |
| Cash from operations | — | — | — | CN¥46.0m | CN¥40.0m | CN¥19.0m | CN¥24.0m | CN¥56.0m |
| Capital spending | −CN¥37.0m | −CN¥9.0m | −CN¥9.0m | −CN¥3.0m | −CN¥2.0m | −CN¥10.0m | −CN¥19.0m | −CN¥10.0m |
| Free cash flow | — | — | — | CN¥43.0m | CN¥38.0m | CN¥9.0m | CN¥5.0m | CN¥46.0m |
| Total assets | CN¥1.92bn | CN¥1.95bn | CN¥1.90bn | CN¥1.89bn | CN¥1.88bn | CN¥1.96bn | CN¥1.96bn | CN¥1.98bn |
| Cash and short-term investments | — | — | — | CN¥290.5m | CN¥246.8m | CN¥271.3m | CN¥249.5m | CN¥393.3m |
| Debt | CN¥440.0m | CN¥451.3m | CN¥445.9m | CN¥97.2m | CN¥435.2m | CN¥437.2m | CN¥432.0m | CN¥571.8m |
| Shareholders' equity | CN¥1.19bn | CN¥1.21bn | CN¥1.21bn | CN¥1.20bn | CN¥1.20bn | CN¥1.23bn | CN¥1.22bn | CN¥1.22bn |
Financial ratios
Data as of 24 Oct 2026
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|
| Operating margin | 6.2% | 10.1% | 7.3% | 9.8% | 17.4% | 12.3% |
| Net margin | 2.8% | 6.6% | 4.5% | 8.1% | 13.4% | 10.6% |
| Return on equity | 1.6% | 4.4% | 3.3% | 5.5% | 9.1% | 5.1% |
| Return on assets | 1.0% | 2.7% | 2.0% | 3.2% | 5.4% | 4.0% |
| Free cash flow yield | 4.0% | 3.9% | 6.1% | 6.8% | 5.1% | 6.5% |
| Revenue growth | -17.1% | -11.1% | 13.1% | -0.1% | 58.7% | -3.7% |
| Earnings growth | -64.5% | 32.2% | -37.8% | -39.2% | 100.9% | -13.1% |
| Current ratio | 4.72x | 3.24x | 2.77x | 2.55x | 3.04x | 2.39x |
| Debt to equity | 0.37x | 0.35x | 0.37x | 0.39x | 0.37x | 0.05x |
| Equity ratio | 63.4% | 62.5% | 59.5% | 59.0% | 59.5% | 78.5% |
| Interest coverage | 1.94x | 3.87x | 3.10x | 3.99x | 10.94x | 122.59x |
| R&D as a share of sales | 2.2% | 2.5% | 2.6% | 2.4% | 1.5% | 1.6% |
| Buybacks as a share of market value | 11.8% | -0.1% | -1.1% | 2.2% | -2.9% | 4.8% |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | -5.9% | 5.8% | 3.3% |
| Operating income | -6.5% | -4.9% | -3.4% |
| Net income | -33.7% | -18.6% | -11.0% |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Operating margin | 7.7% | 6.9% | 9.1% | 11.6% |
| Net margin | 4.9% | 5.6% | 7.6% | 9.9% |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Price to earnings | 135.6 | 45.7 | 73.5 | 47.1 | 48.6 | 202.5 | 44.3 | 29.3 | 15.9 |
| Price to sales | 3.9 | 3.0 | 3.3 | 3.8 | 6.5 | 21.4 | 5.2 | 4.1 | 2.6 |
Dividends and splits
Per share, in the currency the company pays
Paid for 8 years. Last went ex-dividend on 28 May 2026.
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Paid in the year | 0.29 | 0.246 | 0.30 | 0.06 | 0.308 | 0.036 | 0.324 | 0.08 |
- 7-for-5 split · 28 May 2018
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.